A phase I trial of Amplimexon (Imexon Inj) administered daily for 5 days every 3 weeks to patients with metastatic cancer or disseminated malignancy

Trial Profile

A phase I trial of Amplimexon (Imexon Inj) administered daily for 5 days every 3 weeks to patients with metastatic cancer or disseminated malignancy

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2008

At a glance

  • Drugs Imexon (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AmpliMed
  • Most Recent Events

    • 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top